ZCI
BMRN icon

Zevenbergen Capital Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zevenbergen Capital Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-469,407
Closed -$35.7M – 85
2020
Q3 		$35.7M Sell
469,407
-192,223
-29% -$19.4M 0.72% 32
2020
Q2 		$81.6M Buy
661,630
+18,505
+3% +$1.84M 1.95% 18
2020
Q1 		$54.3M Buy
643,125
+28,415
+5% +$2.45M 2.05% 20
2019
Q4 		$52M Buy
614,710
+24,370
+4% +$1.84M 1.93% 20
2019
Q3 		$39.8M Sell
590,340
-47,855
-7% -$3.69M 1.52% 24
2019
Q2 		$54.7M Buy
638,195
+165,445
+35% +$14.2M 1.79% 21
2019
Q1 		$42M Buy
472,750
+47,125
+11% +$4.37M 1.49% 28
2018
Q4 		$36.2M Buy
425,625
+37,750
+10% +$3.59M 1.58% 27
2018
Q3 		$37.6M Sell
387,875
-10,100
-3% -$1.01M 1.19% 34
2018
Q2 		$37.5M Buy
397,975
+133,070
+50% +$11.7M 1.25% 31
2018
Q1 		$21.5M Hold
264,905
– – 0.83% 34
2017
Q4 		$23.6M Sell
264,905
-2,440
-0.9% -$212K 0.98% 33
2017
Q3 		$24.9M Sell
267,345
-16,340
-6% -$1.44M 1.08% 33
2017
Q2 		$25.8M Sell
283,685
-26,674
-9% -$2.43M 1.12% 32
2017
Q1 		$27.2M Sell
310,359
-38,835
-11% -$3.45M 1.25% 32
2016
Q4 		$28.9M Sell
349,194
-60,705
-15% -$5.22M 1.36% 31
2016
Q3 		$37.9M Sell
409,899
-46,060
-10% -$4.34M 1.56% 27
2016
Q2 		$35.5M Sell
455,959
-4,250
-0.9% -$361K 1.66% 28
2016
Q1 		$38M Buy
460,209
+2,452
+0.5% +$200K 1.72% 22
2015
Q4 		$48M Buy
457,757
+44,200
+11% +$4.62M 1.95% 24
2015
Q3 		$43.6M Sell
413,557
-2,375
-0.6% -$317K 1.87% 27
2015
Q2 		$56.9M Buy
415,932
+46,150
+12% +$5.72M 2.21% 22
2015
Q1 		$46.1M Buy
369,782
+345,705
+1,436% +$36.6M 1.93% 25
2014
Q4 		$2.18M Buy
+24,077
New +$2M 0.09% 48

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Zevenbergen Capital Investments's BMRN Position: Q4 2020 in Review

Zevenbergen Capital Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 469,407 shares — an estimated $35.7M sold.

Zevenbergen Capital Investments first reported a position in BMRN in Q4 2014 and held it in 24 quarters. The position peaked at $81.6M in Q2 2020. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Zevenbergen Capital Investments reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 469,407 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $35.7M.
  • Zevenbergen Capital Investments first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 24 quarters.
  • Zevenbergen Capital Investments's BioMarin Pharmaceuticals position peaked at $81.6M in Q2 2020.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Zevenbergen Capital Investments's 13F filing for Q4 2020, filed 10 Feb 2021.